Cellular Research, Undisclosed (published in popular press), Source: http://www.prnewswire.com/news-releases/bd-to-acquire-cellular-research-to-develop-a-leading-genomics-platform-for-single-cell-analysis-300133097.html
|2005 Yale University , BS , Biophysics and Biochemistry|
|2006 Cambridge University , MS , Biotechnology|
|2013 Stanford University , MBA|
Julie Papanek is a healthcare VC at Canaan Partners who brings operational experience from biotechnology and digital health. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development. Julie holds an MBA from Stanford’s Graduate School of Business and earned an MPhil from Cambridge University in BioScience Enterprise and a B.S. from Yale University in Molecular Biophysics and Biochemistry. She is a director at Protagonist Therapeutics and played an active role in Canaan's previous investments in CytomX, Labrys, Glooko, Chrono, Truveris, Aldea Pharmaceuticals, Cellular Research and Dermira.
Within the life sciences, Julie is focused on pre-clinical and early clincial biopharmaceutical companies pursuing novel platforms or biology. Within digital health, Julie has a particular interest in tech companies creating products for the life science sector, consumer affordability, revenue cycle management, and b2b financial products.